The problem is, generally speaking, the more control the manufacture exercises over the distributor, the more they may open themselves up for liability due the the distributor's conduct. If it's me I have counsel advise the bare minimum -- provide instructions, warnings, etc. and leave it to the distributor to read, ensure they understand, and take step necessary to preserve the product for use. A lot will be controlled by the distribution agreement, including indemnity clauses. There is no way, I as a manufacturer, want to be responsible not only for the many distributors but all the users (hospitals, Doctors, etc.) as well.
Rogue CEO refuses to follow proceedures
- Thread starter Bob365
- Start date
Elsmar Forum Sponsor
Thanks Randy, where does our responsibility end for storage of the product? I assume it is the courier who delivers it to the door of the hospital, is that right? We instruct the hospital how to store the product via the IFU and packaging, but we do not audit device user facilities. I believe we have a duty of care to perform due diligence on distributors regardless of whether they have purchased the product or have it on consignment.
HI Bev, thanks for your comment, yes I think you are right the customer is the patient. Our last ISO auditor stated that we should be auditing all distributors, but there is no requirement to audit device user facilities such as hospitals. The hospital purchases the product and at that point we do not hold ourselves responsible for storage, we instruct them but there is no site audit, we expect the hospital regulatory system to ensure that storage of product is performed correctly. There are no such regulatory controls for many distributors that we have come across, maybe they do exist, our initial importer in the US has ISO certification, but none of the sub distributors do.
I need to know whether you all think that distributors should be audited on site in the first instance prior to engagement.
many thanks!
From Grok
In the United States, medical device manufacturers are generally not legally required to formally "assess" their distributors in a standardized or mandated way under federal regulations, such as those enforced by the Food and Drug Administration (FDA). However, manufacturers bear significant responsibilities related to the distribution of their devices to ensure compliance with regulatory requirements and to maintain the safety and effectiveness of their products. Below is a concise overview:
### Key Responsibilities of Medical Device Manufacturers Regarding Distributors:
1. **Quality System Regulation (QSR)**:
- Under the FDA’s Quality System Regulation (21 CFR Part 820), manufacturers must establish and maintain procedures to ensure that their devices are handled, stored, and distributed in a manner that prevents adulteration, misbranding, or compromise of safety and effectiveness.
- While this does not explicitly require "assessing" distributors, manufacturers are expected to exercise oversight to ensure distributors comply with proper storage, handling, and transportation conditions.
2. **Due Diligence and Oversight**:
- Manufacturers are responsible for ensuring that their distributors are competent and capable of meeting regulatory and contractual obligations. This may involve conducting due diligence, such as verifying that distributors have appropriate facilities, processes, and training to handle medical devices.
- Manufacturers may include clauses in distribution agreements requiring distributors to adhere to specific standards, such as Good Distribution Practices (GDP) or compliance with FDA regulations.
3. **Labeling and Traceability**:
- Manufacturers must ensure that distributors do not alter labeling or packaging in ways that could lead to misbranding or adulteration.
- The FDA’s Unique Device Identification (UDI) requirements (21 CFR Part 801) mandate that manufacturers ensure devices are properly tracked through the supply chain, which may involve coordinating with distributors to maintain traceability.
4. **Post-Market Surveillance**:
- Manufacturers are responsible for monitoring the performance of their devices after distribution, including addressing any issues that arise during distribution (e.g., improper storage by a distributor leading to device failure).
- If a distributor’s actions result in adverse events, manufacturers must investigate and report to the FDA as required under 21 CFR Part 803 (Medical Device Reporting).
5. **Risk Management**:
- Under ISO 13485 (which aligns with FDA expectations) and FDA guidance, manufacturers are expected to manage risks throughout the supply chain. This includes ensuring that distributors do not introduce risks (e.g., improper handling of sterile devices).
### Practical Implications:
While the FDA does not explicitly mandate a formal assessment process for distributors, manufacturers typically assess or vet distributors as part of their quality management system to:
- Ensure compliance with regulatory requirements.
- Protect the integrity of their devices.
- Mitigate liability risks.
This assessment might include:
- Evaluating a distributor’s storage facilities, transportation methods, and quality control processes.
- Requiring distributors to provide evidence of compliance with applicable regulations.
- Conducting periodic audits or reviews of distributor performance.
### Exceptions and Context:
- **Third-Party Distributors**: If a manufacturer uses third-party distributors, they remain responsible for ensuring the device reaches the end user in a safe and effective condition. The FDA holds the manufacturer accountable for supply chain issues unless the distributor is explicitly responsible for certain regulatory obligations (e.g., as an importer or reprocessor).
- **Foreign Distributors**: If devices are distributed internationally, manufacturers must ensure compliance with both U.S. regulations and the regulations of the destination country, which may involve additional oversight of distributors.
### Conclusion:
Medical device manufacturers in the U.S. are not explicitly required by the FDA to "assess" distributors in a formal sense, but they are responsible for ensuring that their distribution processes—including the actions of their distributors—comply with FDA regulations and maintain device safety and effectiveness. In practice, this often leads manufacturers to implement assessment or oversight mechanisms as part of their quality systems.
In the United States, medical device manufacturers are generally not legally required to formally "assess" their distributors in a standardized or mandated way under federal regulations, such as those enforced by the Food and Drug Administration (FDA). However, manufacturers bear significant responsibilities related to the distribution of their devices to ensure compliance with regulatory requirements and to maintain the safety and effectiveness of their products. Below is a concise overview:
### Key Responsibilities of Medical Device Manufacturers Regarding Distributors:
1. **Quality System Regulation (QSR)**:
- Under the FDA’s Quality System Regulation (21 CFR Part 820), manufacturers must establish and maintain procedures to ensure that their devices are handled, stored, and distributed in a manner that prevents adulteration, misbranding, or compromise of safety and effectiveness.
- While this does not explicitly require "assessing" distributors, manufacturers are expected to exercise oversight to ensure distributors comply with proper storage, handling, and transportation conditions.
2. **Due Diligence and Oversight**:
- Manufacturers are responsible for ensuring that their distributors are competent and capable of meeting regulatory and contractual obligations. This may involve conducting due diligence, such as verifying that distributors have appropriate facilities, processes, and training to handle medical devices.
- Manufacturers may include clauses in distribution agreements requiring distributors to adhere to specific standards, such as Good Distribution Practices (GDP) or compliance with FDA regulations.
3. **Labeling and Traceability**:
- Manufacturers must ensure that distributors do not alter labeling or packaging in ways that could lead to misbranding or adulteration.
- The FDA’s Unique Device Identification (UDI) requirements (21 CFR Part 801) mandate that manufacturers ensure devices are properly tracked through the supply chain, which may involve coordinating with distributors to maintain traceability.
4. **Post-Market Surveillance**:
- Manufacturers are responsible for monitoring the performance of their devices after distribution, including addressing any issues that arise during distribution (e.g., improper storage by a distributor leading to device failure).
- If a distributor’s actions result in adverse events, manufacturers must investigate and report to the FDA as required under 21 CFR Part 803 (Medical Device Reporting).
5. **Risk Management**:
- Under ISO 13485 (which aligns with FDA expectations) and FDA guidance, manufacturers are expected to manage risks throughout the supply chain. This includes ensuring that distributors do not introduce risks (e.g., improper handling of sterile devices).
### Practical Implications:
While the FDA does not explicitly mandate a formal assessment process for distributors, manufacturers typically assess or vet distributors as part of their quality management system to:
- Ensure compliance with regulatory requirements.
- Protect the integrity of their devices.
- Mitigate liability risks.
This assessment might include:
- Evaluating a distributor’s storage facilities, transportation methods, and quality control processes.
- Requiring distributors to provide evidence of compliance with applicable regulations.
- Conducting periodic audits or reviews of distributor performance.
### Exceptions and Context:
- **Third-Party Distributors**: If a manufacturer uses third-party distributors, they remain responsible for ensuring the device reaches the end user in a safe and effective condition. The FDA holds the manufacturer accountable for supply chain issues unless the distributor is explicitly responsible for certain regulatory obligations (e.g., as an importer or reprocessor).
- **Foreign Distributors**: If devices are distributed internationally, manufacturers must ensure compliance with both U.S. regulations and the regulations of the destination country, which may involve additional oversight of distributors.
### Conclusion:
Medical device manufacturers in the U.S. are not explicitly required by the FDA to "assess" distributors in a formal sense, but they are responsible for ensuring that their distribution processes—including the actions of their distributors—comply with FDA regulations and maintain device safety and effectiveness. In practice, this often leads manufacturers to implement assessment or oversight mechanisms as part of their quality systems.
Kronos147
Trusted Information Resource
If there is a policy that says the new supplier must meet a requirement or barrier that they don't meet, then "the rest of us" should not sign the approval without having the policy changed or asking the new supplier to (or plan to) meet the requirement. If "someone" (read 'CEO') wants to make and exception, they can sign off on the approval.
Same with an inspection.
Let the CEO assume the risk.
How the patient or end user actually uses the product should be a driver. People don’t store Tylenol in the original box it comes in. They store the actual bottle or plastic container of Tylenol. All info for S&E must be clearly on the bottle. End user labeling.
In an ideal world, yes. How do you distinguish between a reputable Distributor and a crook who has paid to have a really professional website created that makes him look like a multi-million dollar turnover organisation that has huge resources and has been in business for decades?
In practice, you may not need to perform the audit yourself, there are other means such as employing a local consultancy to visit and audit on your behalf, previous experience of the Distributor by members of your own staff etc.... but you need to define what your process is, for approving a Distributor (what criteria do you use, what do you expect back from the Distributor in terms of information, reports, feedback, service including response times to questions/instructions, ability to react in case of a recall or requirement to report anything to the relevant health authorities in their area etc)
Yeah what is the source? Seems very contradictory. First says the is no responsibility to assess distributors, but then says manufacturers are responsible which leads to assessment.
The fundamental question still stands, since this a qms thread. What standard clause, or federal gmp regulation requires assessment? In other words, show me the shall.
You should consider opening up your own business for debunking AI advice. Don’t let that skill go to waste.
Similar threads
